Skip to main content

華領醫藥將於11月12日發佈Dorzagliatin單藥治療III期臨床試驗24周頂線資料（HMM0301）

Written by Customer Service on . Posted in Public Companies.

上海, Nov. 08, 2019 (GLOBE NEWSWIRE) — 華領醫藥（香港主機板股票代碼：2552）是一家專注於研發治療全球2型糖尿病原創口服新藥的生物技術公司，總部位於上海。今天華領醫藥宣佈，dorzagliatin單藥治療臨床試驗(HMM0301)的24周頂線資料將於2019年11月12日公佈，管理層將通過電話會議陳述該試驗結果並回答各種問題。  
關於HMM0301
HMM0301[NCT03173391] 是一項以中國未用藥2型糖尿病患者為目標，將dorzagliatin定位為一線療法的III期註冊臨床試驗。該臨床試驗是一項雙盲、安慰劑對照的臨床試驗，受試者以dorzagliatin對比安慰劑2：1的比例隨機分配，在雙盲治療的24周之內評估dorzagliatin的有效性和安全性，隨後進入28周開放治療期和後期觀察期，總共52周。主要臨床終點是24周。該試驗由中華醫學會糖尿病學會主任委員朱大龍教授領導，在全國40多個臨床中心進行，已於2019年2月28日完成受試者入組。關於Dorzagliatin (HMS5552)
Dorzagliatin是全球首創雙作用的葡萄糖激酶啟動劑，旨在通過恢復2型糖尿病患者的葡萄糖穩態來控制糖尿病漸進性退變性疾病發展。通過修復葡萄糖激酶的葡萄糖感測器功能的缺陷, dorzagliatin具有恢復2型糖尿病患者受損的血糖穩態狀態下的潛力，可作為治療該疾病的一線護理治療標準，或作為與目前批准的抗糖尿病藥物聯合使用的基礎治療。關於華領
華領醫藥是一家立足中國，針對全球糖尿病患者尚未滿足的臨床需求，研發全球原創新藥的生物技術公司。華領醫藥彙聚全球高端人才和科技資源，以國際頂級生物醫藥投資團隊為依託，成功實現了全球首創糖尿病新藥dorzagliatin在中國完成藥品可開發性臨床驗證，率先進入註冊性臨床試驗階段。目前公司已在中國開展2個III期臨床試驗以及在美國進行2個I期試驗治療成人2型糖尿病。公司將啟動藥品生命週期管理相關臨床試驗，並拓展糖尿病個性化治療和管理的先進理念，聯合中國和美國糖尿病領域專家，實現對糖尿病和代謝性疾病及其併發症的有效控制。 詳情垂詢：
華領醫藥
電郵：

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.